HUTCHMED has announced the completion of patient enrollment in a Phase II trial for fanregratinib (HMPL-453), aimed at treating intrahepatic cholangiocarcinoma (IHCC) patients with FGFR2 fusion ...
Hutchmed Completes Enrollment in Phase II Trial of Fanregratinib in FGFR2-Altered Cholangiocarcinoma
NEW YORK – Hutchmed on Thursday said it has completed enrollment of a Phase II trial in China testing the FGFR1/2/3 inhibitor fanregratinib in patients with advanced intrahepatic cholangiocarcinoma ...
“The Department of Health and Human Services’ assistant secretary for public affairs informed the CDC that HHS Secretary Robert F. Kennedy Jr. wanted advertisements that promote the idea of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback